-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Down 15.7% in September
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Down 15.7% in September
Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Rating) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 401,400 shares, a decline of 15.7% from the August 31st total of 476,400 shares. Based on an average trading volume of 377,400 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.8% of the shares of the company are sold short.
Connect Biopharma Trading Up 5.7 %
Shares of NASDAQ:CNTB traded up $0.07 during mid-day trading on Friday, reaching $1.29. 156,903 shares of the company traded hands, compared to its average volume of 76,999. The company's 50 day moving average price is $1.30 and its 200-day moving average price is $1.51. Connect Biopharma has a 52 week low of $0.56 and a 52 week high of $24.70.
Get Connect Biopharma alerts:Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. bought a new position in Connect Biopharma in the 4th quarter worth approximately $6,438,000. Citadel Advisors LLC bought a new position in Connect Biopharma in the 2nd quarter worth approximately $357,000. DAFNA Capital Management LLC bought a new position in Connect Biopharma in the 2nd quarter worth approximately $218,000. Kynam Capital Management LP bought a new position in Connect Biopharma in the 1st quarter worth approximately $688,000. Finally, UBS Group AG boosted its stake in Connect Biopharma by 5,552.1% in the 2nd quarter. UBS Group AG now owns 105,185 shares of the company's stock worth $91,000 after purchasing an additional 103,324 shares during the period. 27.19% of the stock is currently owned by institutional investors.
About Connect Biopharma
(Get Rating)Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
Featured Stories
- Get a free copy of the StockNews.com research report on Connect Biopharma (CNTB)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Thor Industries Hammers Out A Bottom
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Rating) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 401,400 shares, a decline of 15.7% from the August 31st total of 476,400 shares. Based on an average trading volume of 377,400 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.8% of the shares of the company are sold short.
康乃德生物控股有限公司(納斯達克:CNTB-GET評級)在9月份看到空頭股數的股價大幅下跌。截至9月15日,空頭股數共有40.14萬股,較8月31日的47.64萬股減少15.7%。以377,400股的平均成交量計算,目前天數與回補比率為1.1天。該公司約0.8%的股份被賣空。
Connect Biopharma Trading Up 5.7 %
康乃德生物交易價格上漲5.7%
Shares of NASDAQ:CNTB traded up $0.07 during mid-day trading on Friday, reaching $1.29. 156,903 shares of the company traded hands, compared to its average volume of 76,999. The company's 50 day moving average price is $1.30 and its 200-day moving average price is $1.51. Connect Biopharma has a 52 week low of $0.56 and a 52 week high of $24.70.
納斯達克:CNTB股價週五午盤上漲0.07美元,至1.29美元。該公司有156,903股易手,而其平均成交量為76,999股。該公司的50日移動均線價格為1.30美元,200日移動均線價格為1.51美元。康乃德生物的52周低點為0.56美元,52周高點為24.70美元。
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. bought a new position in Connect Biopharma in the 4th quarter worth approximately $6,438,000. Citadel Advisors LLC bought a new position in Connect Biopharma in the 2nd quarter worth approximately $357,000. DAFNA Capital Management LLC bought a new position in Connect Biopharma in the 2nd quarter worth approximately $218,000. Kynam Capital Management LP bought a new position in Connect Biopharma in the 1st quarter worth approximately $688,000. Finally, UBS Group AG boosted its stake in Connect Biopharma by 5,552.1% in the 2nd quarter. UBS Group AG now owns 105,185 shares of the company's stock worth $91,000 after purchasing an additional 103,324 shares during the period. 27.19% of the stock is currently owned by institutional investors.
一些對衝基金最近改變了他們在該股的頭寸。Adage Capital Partners GP L.L.C.在第四季度購買了康乃德生物的一個新頭寸,價值約643.8萬美元。Citadel Advisors LLC在第二季度購買了康乃德生物的一個新頭寸,價值約357,000美元。達夫納資本管理有限公司在第二季度購買了一個新的康乃德生物頭寸,價值約218,000美元。凱納姆資本管理有限公司在第一季度購買了一個新的康乃德生物頭寸,價值約68.8萬美元。最後,瑞銀集團在第二季度增持了5,552.1%的康乃德生物股份。瑞銀集團(UBS Group AG)在此期間又購買了103,324股,目前持有105,185股該公司股票,價值91,000美元。該公司27.19%的股票目前由機構投資者持有。
About Connect Biopharma
關於康乃德生物
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
康乃德生物控股有限公司是一家臨牀階段的生物製藥公司,專注於發現和開發用於治療嚴重自身免疫性疾病和炎症的免疫調節劑。該公司的主要候選產品是CBP-201,這是一種抗白細胞介素4受體α抗體,正處於IIb階段臨牀試驗,用於治療炎症性過敏性疾病,如特應性皮炎、哮喘和慢性鼻竇炎伴鼻息肉。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Connect Biopharma (CNTB)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Thor Industries Hammers Out A Bottom
- 在康乃德生物上免費獲取斯托克新聞網研究報告(CNTB)
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat:回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 利潤下降對CarMax價值主張的挑戰
- 雷神工業走出谷底
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受康乃德生物日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對康乃德生物及相關公司評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧